Bristol-Myers Squibb Company is committed to organizational resilience through its strategic initiatives aimed at maintaining operational flexibility and adapting to external pressures. The company is focused on discovering, developing, and delivering innovative medicines that address serious unmet medical needs, which reflects a proactive approach to business continuity and resource allocation. In 2016, the company announced an evolution to its operating model, which aims to drive continued success through a more focused investment in commercial opportunities for key brands and markets, enhancing its operational capabilities and strategic agility. This new operating model is designed to deliver the strategic, financial, and operational flexibility necessary to invest in the highest priorities across the company. The company continues to invest significantly in its deep pipeline of innovative medicines, which supports its resilience strategies by enabling it to confront and benefit from sudden disruptive changes in the market. The focus on inter-organizational collaboration and partnerships is essential for driving transformation and maintaining competitive advantage in a turbulent business environment. The company remains well-resourced in its first-line lung development programs and continuously seeks ways to strengthen its broad portfolio, which is indicative of its commitment to adaptability and future orientation. Additionally, the company monitors inventory levels and adjusts its sales practices to ensure compliance with regulatory requirements, reflecting an awareness of operational constraints and the need for effective event management. The emphasis on continuous improvement and the establishment of a business risk and disclosure group further demonstrate the company's focus on enhancing organizational health and resilience. By maintaining a diversified portfolio and a disciplined approach to capital allocation, Bristol-Myers Squibb aims to ensure its survival and success in the face of environmental disruptions and market volatility. The companyâ€™s strategic planning includes anticipating customer needs and adapting to changes in the competitive landscape, which are critical components of its organizational resilience. Overall, Bristol-Myers Squibb's commitment to innovation, operational continuity, and strategic foresight positions it to effectively navigate complex situations and maintain performance under pressure.